Huangjin Shuangshen decoction alleviates chronic atrophic gastritis by suppressing TNF/NF-κB signaling and promoting CFTR-associated gastric mucosal barrier repair
-
By
-
Shuo Zhang
-
Shuya Zhang
-
Mengyi Wang
-
Xueru Huang
-
Chen Huang
-
Tao Jiang
-
Guangji Zhang
-
July 10, 2026
-
Clinical Scorecard: Huangjin Shuangshen Decoction Mitigates Chronic Atrophic Gastritis by Inhibiting TNF/NF-κB Pathway and Enhancing Repair of CFTR-Related Gastric Mucosal Barrier
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Atrophic Gastritis |
| Key Mechanisms | Inhibition of TNF/NF-κB signaling and enhancement of CFTR-related gastric mucosal barrier repair |
| Target Population | Patients with chronic atrophic gastritis |
| Care Setting | Clinical research on gastritis-related disorders |
Key Highlights
- HJSS alleviates gastric mucosal atrophy and histopathological injury.
- Improves gastric function and reduces inflammatory burden.
- Promotes recovery of gastric mucosal barrier-associated molecules.
- Involves suppression of TNF/NF-κB signaling.
- Demonstrates protective effects in both in vivo and in vitro models.
Guideline-Based Recommendations
Diagnosis
- Histopathological evaluation of gastric mucosa.
Management
- Use of Huangjin Shuangshen Decoction for therapeutic intervention.
Monitoring & Follow-up
- Assessment of gastric function indices and inflammatory mediators.
Risks
- Potential progression to intestinal metaplasia and gastric cancer if untreated.
Patient & Prescribing Data
Individuals diagnosed with chronic atrophic gastritis.
HJSS may provide a multi-faceted approach to managing inflammation and enhancing mucosal barrier integrity.
Clinical Best Practices
- Integrate traditional Chinese medicine with conventional treatment strategies.
- Monitor for changes in gastric mucosal integrity and inflammatory markers.
Related Resources & Content
